International Registry for Severe Chronic Neutropenia
Collecte de données
Données recueillies à un instant précis - TransversaleCytopénie+8
+ Agranulocytose
+ Maladies hématologiques et lymphatiques
Autre
Méthodes concernant des questions de recherche très spécifiques.Résumé
Date de début de l'étude : 1 juin 1994
Date à laquelle le premier participant a commencé l'étude.PROTOCOL OUTLINE: Patients are treated by the referring physician as medically indicated. Clinical data are collected at baseline and then every 6 months.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.1000 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Autre
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.À partir de 3 mois
Tranche d'âge des participants éligibles à participer.Volontaires sains non autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
Inclusion Criteria - Subjects are eligible for enrollment if they meet the following criteria: A confirmed diagnosis of severe chronic neutropenia based on documented absolute neutrophil counts of less than 0.5x109/L on at least three occasions in the three months prior to enrollment. For subjects with presumed cyclic neutropenia, documentation of at least two neutrophil cycles is preferred. Documentation should include the nadirs with neutrophil counts of less than 200 followed by a clear increase in the counts generally to at least 500 to 1000 followed by a second nadir, usually expected to occur at about three weeks after the first nadir, i.e., cycling with a three week periodicity. Documentation with at least six weeks of counts and two expected nadirs is preferred. Cases not showing clear oscillations will be categorized as congenital (if neutropenia or neutropenic complications appear to have occurred from birth) or idiopathic (if all symptoms in evidence point to an acquired disorder occurring after the first year of life). Bone marrow aspiration consistent with the diagnosis of congenital, cyclic or idiopathic neutropenia. In all of these conditions, it is expected that the marrow aspirate evaluation at the time of neutropenia will show a deficiency of mature neutrophils. An exception is myelokathexis, a condition with large accumulations of neutrophils with pycnotic nuclei in the marrow. Bone marrow aspirates may show some dyspoiesis of the neutrophil lineage, but abnormalities of erythropoiesis or platelet formation are, in general, inconsistent with the diagnosis of SCN. Normal cytogenetic evaluation. The only exception being cases of well documented severe congenital neutropenia with preferably previously documented normal cytogenetic evaluation will now be enrolled in the Registry at the time of evolution to leukemia. History of recurrent infections (i.e., severe mouth ulcers, gingivitis and sinusitis). Age greater than three months. Independent of hematological parameters, subjects with the following diagnoses may be included: Shwachman-Diamond syndrome (SDS), glycogen storage disease type 1b (GSD1b), Barth syndrome, and Cohen's syndrome. Subjects with moderately severe chronic neutropenia (i.e., ANC less than 1.0x109/L) and recurrent severe infections (i.e., deep tissue infections of subcutaneous areas, lungs, liver, etc.). Immune neutropenia with positive anti-neutrophil antibodies meeting criteria in 1, 3, 5 and 6. All SCN subjects originally enrolled in Amgen-sponsored SCN studies. Exclusion Criteria Neutropenia known to be drug induced Primary myelodysplasia Primary leukemia Aplastic anemia Known HIV disease Systemic autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus Chemotherapy-induced neutropenia (within the last 5 years)
Plan de l'étude
Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.3 groupes d'intervention sont désignés dans cette étude
Cette étude ne comporte pas de groupe placebo.
Groupes de traitement
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 10 sites
Dana-Farber/Boston Children¹s Cancer and Blood Disorders Center
Boston, United StatesOuvrir Dana-Farber/Boston Children¹s Cancer and Blood Disorders Center dans Google MapsUniversity of Massachusetts
Worcester, United StatesUniversity of Michigan
Ann Arbor, United StatesSt. Joseph's Children's Hospital
Paterson, United States